Alchemia banks on 2010

By Dylan Bushell-Embling
Thursday, 02 October, 2008

Alchemia [ASX: ACL] has recorded an $11 million loss for the financial year but reports a healthy cash reserve of $15.3 million.

Equity increased from around $87 million to $102 million.

The company expects to go into profit in 2010. Its generic fondaparinux, a copy of GSK’s Arixta, for venous thromboembolism, is scheduled for market launch in the US next year through its partner Dr Reddy’s.

Farm animals and aquaculture cryopreservation partnership announced

Vitrafy Life Sciences Limited has announced that it has entered a 12-month exclusive agreement...

Babies of stressed mothers likely to get their teeth earlier

Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...

Customised immune cells used to fight brain cancer

Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...

Content from other channels on our network

Carbon-conversion technology creates chemicals for jet fuel

Novel energy storage system to decarbonise buildings

F-Gas Regulation: Turning necessity into opportunity

Tiny gold spheres could improve solar energy harvesting

Methane reduction trial uses nature-based supplement

Advanced inspection systems that go above and beyond to safeguard food

Boost Efficiency with Weidmüller PUSH IN Terminal Blocks

The AI Advantage: Why Food Manufacturers Can't Afford to Wait

Afnor acquires HACCP Australia and HACCP International

Solving the limitations for paper packaging with coating strategy

The Machinery Regulation will be mandatory in less than a year — are you ready?

Siemens introduces industrial metaverse design environment

IFR predicts the top five global robotics trends for 2026

UNSW researchers find uses for textiles and other wastes

Queensland BESS project gets grid connection approval